~~<i id='2258154409'><strike id='2258154409'><tt id='2258154409'><pre id='2258154409'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：fashion 2025-09-06 05:38:45 Page View：86342

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Newly revealed memo details efforts to keep Trump in power following election loss
Next article： Malaria cases in Florida and Texas: Here’s what you need to know

comprehensive

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

Neuroscience’s long legacy of racism

AdobeManypartsofneuroscienceresearchhavearaceproblem.Blackpeopleareoftenexcludedfromstudiesduetothet

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Nurses recount patients attacks

Violenceagainstdoctors,nurses,andotherhealth-careprovidersisontherise.FredDufour/AFP/GettyImagesViol